(Boursier.com) — TME Pharma NV, a biotechnology company specializing in the development of new therapies for the treatment of cancer by targeting the tumor microenvironment (TME), announces a positive update on the two-year survival of patients with newly diagnosed glioblastoma receiving NOX-A12, TME Pharma’s CXCL12 inhibitor, in combination with the VEGF inhibitor bevacizumab and radiotherapy.
Two of the six glioblastoma patients who participated in this expansion arm of the phase 1/2 GLORIA trial have survived more than 24 months since the start of treatment. Both of these patients had tumors that, at some point during treatment, disappeared completely or achieved a near-complete reduction (more than 99%) in size. The first patient to pass the two-year survival milestone maintained a normal physical and cognitive state, presenting at this stage only minimal symptoms specific to the disease. This results in preserved quality of life, as evidenced by the patient’s continued ability to engage in hobbies, leisure activities, and social interactions.
The clinical condition of the second patient at the last evaluation at 23 months was stable, although some of his neurological functions were partially affected. This patient’s progress is also remarkable in that he has not received any therapy likely to prolong his survival over the past 18 months, having decided to stop the NOX-A12 combination treatment, following a reduction almost complete tumor observed by MRI.
In February, TME Pharma announced that the final median overall survival of the NOX-A12 cohort reached an unprecedented 19.9 months. This survival rate compares very favorably to that of a standard of care reference cohort, which achieved a median overall survival of approximately 10 months, and exceeds the level of survival obtained in all relevant competing therapeutic trials, as estimated by TME Pharma, in newly diagnosed glioblastoma patients resistant to standard chemotherapy.
©2024 Boursier.com